172 related articles for article (PubMed ID: 7809082)
1. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium.
Buck KJ; Amara SG
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12584-8. PubMed ID: 7809082
[TBL] [Abstract][Full Text] [Related]
2. Discrete structural domains and cell-specific expression determine functional selectivity of the dopamine and norepinephrine transporters.
Buck KJ; Lorang D; Amara SG
NIDA Res Monogr; 1996; 161():154-75. PubMed ID: 8784850
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter mutants selectively enhance MPP+ transport.
Kitayama S; Wang JB; Uhl GR
Synapse; 1993 Sep; 15(1):58-62. PubMed ID: 8310426
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and characterization of an L-epinephrine transporter from sympathetic ganglia of the bullfrog, Rana catesbiana.
Apparsundaram S; Moore KR; Malone MD; Hartzell HC; Blakely RD
J Neurosci; 1997 Apr; 17(8):2691-702. PubMed ID: 9092590
[TBL] [Abstract][Full Text] [Related]
5. Structural domains of chimeric dopamine-noradrenaline human transporters involved in the Na(+)- and Cl(-)-dependence of dopamine transport.
Syringas M; Janin F; Mezghanni S; Giros B; Costentin J; Bonnet JJ
Mol Pharmacol; 2000 Dec; 58(6):1404-11. PubMed ID: 11093780
[TBL] [Abstract][Full Text] [Related]
6. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter.
Pifl C; Hornykiewicz O; Giros B; Caron MG
J Pharmacol Exp Ther; 1996 Jun; 277(3):1437-43. PubMed ID: 8667208
[TBL] [Abstract][Full Text] [Related]
7. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants.
Buck KJ; Amara SG
Mol Pharmacol; 1995 Dec; 48(6):1030-7. PubMed ID: 8848002
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.
Pifl C; Giros B; Caron MG
J Neurosci; 1993 Oct; 13(10):4246-53. PubMed ID: 8410185
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptake.
Syringas M; Janin F; Giros B; Costentin J; Bonnet JJ
Br J Pharmacol; 2001 Jun; 133(3):387-94. PubMed ID: 11375255
[TBL] [Abstract][Full Text] [Related]
10. MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters.
Kitayama S; Mitsuhata C; Davis S; Wang JB; Sato T; Morita K; Uhl GR; Dohi T
Biochim Biophys Acta; 1998 Sep; 1404(3):305-13. PubMed ID: 9739158
[TBL] [Abstract][Full Text] [Related]
11. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters.
Giros B; Wang YM; Suter S; McLeskey SB; Pifl C; Caron MG
J Biol Chem; 1994 Jun; 269(23):15985-8. PubMed ID: 8206893
[TBL] [Abstract][Full Text] [Related]
12. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux.
Wall SC; Gu H; Rudnick G
Mol Pharmacol; 1995 Mar; 47(3):544-50. PubMed ID: 7700252
[TBL] [Abstract][Full Text] [Related]
13. Cocaine inhibits the release of MPP+ but not dopamine through the rat dopamine transporter.
Kitayama S; Morita K; Dohi T
Eur J Pharmacol; 1996 Aug; 309(1):107-9. PubMed ID: 8864700
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.
Kitayama S; Shimada S; Xu H; Markham L; Donovan DM; Uhl GR
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7782-5. PubMed ID: 1502198
[TBL] [Abstract][Full Text] [Related]
15. The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function.
Lee SH; Kang SS; Son H; Lee YS
Biochem Biophys Res Commun; 1998 May; 246(2):347-52. PubMed ID: 9610361
[TBL] [Abstract][Full Text] [Related]
16. Regulation of dopamine and MPP+ transport by catecholamine transporters.
Dohi T; Kitayama S; Morioka N; Kumagai K; Mitsuhata C; Morita K; Kozai K; Lin Z; Uhl GR
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Apr; 24(2):43-7. PubMed ID: 15164608
[TBL] [Abstract][Full Text] [Related]
17. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence.
Gu H; Wall SC; Rudnick G
J Biol Chem; 1994 Mar; 269(10):7124-30. PubMed ID: 8125921
[TBL] [Abstract][Full Text] [Related]
18. Species differences in functions of dopamine transporter: paucity of MPP+ uptake and cocaine binding in bovine dopamine transporter.
Lee SH; Rhee J; Koh JK; Lee YS
Neurosci Lett; 1996 Aug; 214(2-3):199-201. PubMed ID: 8878118
[TBL] [Abstract][Full Text] [Related]
19. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
20. Cell-specific sorting of biogenic amine transporters expressed in epithelial cells.
Gu HH; Ahn J; Caplan MJ; Blakely RD; Levey AI; Rudnick G
J Biol Chem; 1996 Jul; 271(30):18100-6. PubMed ID: 8663573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
